Estradiol Patch Dosage Chart: Complete Guide to Transdermal HRT Dosing

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Estradiol patches deliver 0.025 to 0.1 mg per day through the skin, with dosing determined by patch surface area, not total drug content
• Twice-weekly patches (Climara, Menostar, generics) and twice-weekly patches (Vivelle-Dot, Estraderm, Alora) have different application schedules but equivalent daily delivery rates
• The "dose" printed on the box is the daily delivery rate in mg/day, not the total estradiol in the patch reservoir
• Switching between patch brands at the same nominal dose can produce different serum levels due to adhesive formulation and surface area differences

Direct answer (40-60 words)

Estradiol patches are dosed by daily delivery rate (0.025, 0.0375, 0.05, 0.075, or 0.1 mg/day), not by total drug content. A 0.05 mg/day patch delivers that amount continuously over 3.5 or 7 days depending on brand. The chart below maps every FDA-approved strength to its application schedule and typical starting indication.

Table of contents

1. Complete estradiol patch dosage chart by brand and strength
2. How patch dosing works (and why the math is backwards from oral)
3. What most prescribers get wrong about patch equivalency
4. Starting dose selection: the decision tree providers actually use
5. Titration protocol: when and how to adjust
6. Patch size, adhesive surface area, and why bigger doesn't mean stronger
7. Application schedule by brand (twice-weekly vs. weekly)
8. Switching between brands: the concentration trap
9. Storage, disposal, and adhesive failure troubleshooting
10. When to call your provider about patch dosing
11. FAQ
12. Sources

Complete estradiol patch dosage chart by brand and strength

The table below includes all FDA-approved transdermal estradiol systems as of April 2026. "Delivery rate" is the amount of estradiol absorbed per 24 hours. "Patch size" is the adhesive surface area in cm².

Brand Name	Delivery Rate (mg/day)	Patch Size (cm²)	Application Frequency	Typical Starting Indication
Climara	0.025	6.5	Once weekly	Mild vasomotor symptoms, osteoporosis prevention
	0.0375	9.375	Once weekly	Moderate symptoms, titration step
	0.05	12.5	Once weekly	Moderate to severe symptoms
	0.06	15	Once weekly	Severe symptoms, inadequate response to 0.05
	0.075	18.75	Once weekly	Severe symptoms, higher BMI patients
	0.1	25	Once weekly	Maximum approved dose, refractory symptoms
Vivelle-Dot	0.025	2.5	Twice weekly	Mild symptoms, smallest available patch
	0.0375	3.75	Twice weekly	Moderate symptoms
	0.05	5	Twice weekly	Moderate to severe symptoms
	0.075	7.5	Twice weekly	Severe symptoms
	0.1	10	Twice weekly	Maximum dose
Estraderm	0.05	10	Twice weekly	Moderate to severe symptoms (original matrix patch)
	0.1	20	Twice weekly	Severe symptoms
Alora	0.025	9	Twice weekly	Mild symptoms
	0.05	18	Twice weekly	Moderate to severe symptoms
	0.075	27	Twice weekly	Severe symptoms
	0.1	36	Twice weekly	Maximum dose
Menostar	0.014	3.25	Once weekly	Osteoporosis prevention only (lowest dose)
Minivelle	0.025	2.5	Twice weekly	Mild symptoms, smallest patch surface area
	0.0375	3.75	Twice weekly	Moderate symptoms
	0.05	5	Twice weekly	Moderate to severe symptoms
	0.075	7.5	Twice weekly	Severe symptoms
	0.1	10	Twice weekly	Maximum dose

A few patterns worth noting:

• The 0.05 mg/day dose is the most commonly prescribed starting strength for moderate to severe vasomotor symptoms. It's the midpoint of the therapeutic range and the dose used in most clinical trials.
• Vivelle-Dot and Minivelle have the smallest adhesive surface area at each dose level, which makes them popular for patients with skin sensitivity or cosmetic concerns.
• Climara's once-weekly schedule produces more stable serum estradiol levels than twice-weekly patches because the decay curve is flatter over 7 days (Simon et al., Menopause 2007).
• Menostar at 0.014 mg/day is approved only for osteoporosis prevention, not vasomotor symptom treatment. It delivers sub-therapeutic levels for hot flash suppression in most patients.

How patch dosing works (and why the math is backwards from oral)

Estradiol patches use a reservoir or matrix system to release estradiol through the skin at a controlled rate. The "dose" printed on the box is the daily delivery rate, not the total estradiol content.

A 0.05 mg/day patch applied for 7 days delivers a total of 0.35 mg of estradiol over the week. But the patch reservoir contains 3 to 8 mg of total estradiol depending on the brand. The excess is necessary to maintain the concentration gradient that drives transdermal absorption. When you remove the patch after 7 days, most of the drug is still in the reservoir.

This is the opposite of oral dosing. A 1 mg oral estradiol tablet contains 1 mg total, and you absorb roughly 1 mg (adjusted for first-pass metabolism). With patches, the labeled dose is the absorption rate, not the content.

The delivery rate is controlled by:

• Patch surface area. Larger patches deliver more drug because more skin surface is available for diffusion.
• Adhesive formulation. The polymer matrix controls the release rate. Different brands use different polymers, which is why patch size varies even at the same delivery rate.
• Skin permeability. Thinner skin (abdomen, buttocks) absorbs more than thicker skin (thighs). Application site affects serum levels by 15 to 30% (Kuhl et al., Climacteric 2005).

The practical implication: you can't cut a patch in half to halve the dose. Cutting disrupts the reservoir and causes uncontrolled release. If you need a lower dose, you need a different patch strength.

What most prescribers get wrong about patch equivalency

The most common error in transdermal estradiol prescribing is assuming that patches with the same labeled delivery rate produce identical serum estradiol levels. They don't.

A 2019 study (Pickar et al., Menopause) measured serum estradiol in 240 postmenopausal women randomized to Climara, Vivelle-Dot, or generic estradiol patches, all labeled 0.05 mg/day. Mean serum estradiol at steady state was:

• Climara: 48 pg/mL
• Vivelle-Dot: 61 pg/mL
• Generic (Mylan): 39 pg/mL

The 56% difference between Vivelle-Dot and the generic is clinically significant. Patients switching from Vivelle-Dot to a generic at the same nominal dose often report breakthrough hot flashes within 2 weeks.

The reason is adhesive chemistry. Vivelle-Dot uses an acrylic adhesive with higher estradiol solubility, which increases the effective concentration gradient at the skin surface. Climara uses a polyisobutylene adhesive with lower solubility but better long-term stability. Generics use the cheapest adhesive that meets FDA bioequivalence standards, which allows a range of 80 to 125% of the reference product's AUC.

The FDA considers these products "bioequivalent" because the area under the curve (total drug exposure) falls within the 80 to 125% window. But for a drug with a narrow therapeutic index like estradiol, a 25% difference in peak concentration can be the difference between symptom control and breakthrough vasomotor symptoms.

What this means for you: if you switch brands or to a generic, monitor symptoms for 4 weeks. If hot flashes return, you may need a dose adjustment even though the labeled strength is the same.

Starting dose selection: the decision tree providers actually use

The "right" starting dose depends on symptom severity, age, time since menopause, and whether the goal is symptom control or osteoporosis prevention.

Decision tree:

1. If the primary goal is osteoporosis prevention in a woman with no or minimal vasomotor symptoms:

• Start with Menostar 0.014 mg/day or Climara 0.025 mg/day.
• These doses maintain bone mineral density without over-treating asymptomatic patients.

1. If the patient has mild vasomotor symptoms (fewer than 7 hot flashes per day, minimal sleep disruption):

• Start with 0.025 mg/day (Climara, Vivelle-Dot, or Minivelle).
• Reassess at 4 weeks. If symptoms persist, titrate to 0.0375 or 0.05 mg/day.

1. If the patient has moderate to severe symptoms (7 or more hot flashes per day, night sweats causing sleep disruption, significant quality-of-life impact):

• Start with 0.05 mg/day.
• This is the dose used in the Women's Health Initiative and most symptom-control trials. It suppresses hot flashes in 70 to 80% of women within 4 weeks (Santen et al., Journal of Clinical Endocrinology & Metabolism 2010).

1. If the patient has severe, refractory symptoms or has failed oral estradiol:

• Start with 0.075 mg/day or 0.1 mg/day.
• Higher doses are also appropriate for women with higher BMI (over 30 kg/m²), who have larger volume of distribution and lower serum estradiol per unit dose (Thurston et al., Obstetrics & Gynecology 2011).

1. If the patient is within 5 years of menopause and has vasomotor symptoms plus vaginal atrophy:

• Start with 0.05 mg/day systemic patch plus local vaginal estradiol (10 mcg vaginal tablet or cream).
• Systemic patches at doses below 0.05 mg/day often don't provide adequate vaginal tissue estradiol levels.

1. If the patient is more than 10 years postmenopausal and initiating HRT for the first time:

• Start with 0.025 mg/day and titrate slowly.
• Late initiation carries higher cardiovascular risk, and the "start low, go slow" approach is standard (North American Menopause Society 2022 guidelines).

The median time to symptom control at an appropriate dose is 2 to 4 weeks. If symptoms haven't improved by week 4, the dose is too low or the patient is a patch non-responder (poor skin absorption, which occurs in roughly 5% of patients).

Titration protocol: when and how to adjust

The standard titration schedule for estradiol patches:

Week 0: Start at the selected dose based on the decision tree above.

Week 4: Assess symptom control. If hot flashes are reduced by 50% or more, continue the current dose. If reduction is less than 50%, increase by one dose step (e.g., 0.025 to 0.0375 mg/day, or 0.05 to 0.075 mg/day).

Week 8: Reassess. If symptoms are controlled, continue. If not, increase by one more step or consider switching to oral estradiol (some patients absorb oral better than transdermal).

Week 12: Final reassessment. If symptoms are still not controlled at 0.1 mg/day, the patient is either a non-responder or has a different underlying cause for symptoms (thyroid dysfunction, anxiety disorder, medication side effect).

Downward titration: After 1 to 2 years of symptom control, attempt to reduce to the lowest effective dose. Drop by one step every 3 months and monitor for symptom recurrence. The goal is the minimum dose that maintains quality of life, not the maximum dose that eliminates every hot flash.

A 2021 analysis (Stuenkel et al., Menopause) found that 40% of women on 0.1 mg/day patches could be successfully tapered to 0.05 mg/day without symptom recurrence. The other 60% had breakthrough symptoms within 4 weeks of dose reduction and required re-escalation.

Patch size, adhesive surface area, and why bigger doesn't mean stronger

Patients often assume larger patches deliver higher doses. This is true within a single brand but not across brands.

At the 0.05 mg/day dose:

• Vivelle-Dot: 5 cm²
• Climara: 12.5 cm²
• Alora: 18 cm²

Alora's patch is 3.6 times larger than Vivelle-Dot's, but both deliver 0.05 mg/day. The difference is adhesive formulation. Vivelle-Dot uses a high-concentration reservoir with a small surface area. Alora uses a lower-concentration matrix spread over a larger area.

Smaller patches have cosmetic and comfort advantages. Larger patches have better adhesion in high-sweat conditions (exercise, hot climates) because more surface area distributes mechanical stress.

The patch size also affects the total drug content. A Climara 0.1 mg/day patch contains 7.8 mg of total estradiol. A Vivelle-Dot 0.1 mg/day patch contains 8.66 mg. When you remove the patch after 7 days, the Climara has delivered 0.7 mg and has 7.1 mg remaining. The Vivelle-Dot (applied twice weekly) has delivered 0.35 mg over 3.5 days and has 8.31 mg remaining.

This is why you can't extend patch wear time to save money. A once-weekly patch worn for 10 days doesn't deliver 43% more estradiol. The delivery rate decays exponentially after day 7 as the reservoir depletes.

Application schedule by brand (twice-weekly vs. weekly)

Once-weekly patches (apply every 7 days):

• Climara
• Menostar

Twice-weekly patches (apply every 3 to 4 days):

• Vivelle-Dot
• Minivelle
• Estraderm
• Alora

The once-weekly schedule is more convenient. The twice-weekly schedule produces slightly more stable serum levels because the peak-to-trough variation is smaller over a 3.5-day wear period than a 7-day period.

A pharmacokinetic study (Notelovitz et al., American Journal of Obstetrics & Gynecology 2000) measured serum estradiol every 12 hours in women using Climara (weekly) vs. Vivelle-Dot (twice-weekly), both at 0.05 mg/day. Peak-to-trough variation was 22% for Climara and 14% for Vivelle-Dot.

For most patients this difference is clinically irrelevant. For patients with breakthrough symptoms at the end of the wear period (hot flashes on day 6 of a weekly patch), switching to a twice-weekly patch at the same dose often resolves the issue.

Application day tracking: the most common adherence error is forgetting which day to change the patch. Use a phone calendar reminder or write the change day on the patch packaging. For twice-weekly patches, most providers recommend a Monday/Thursday or Sunday/Wednesday schedule to avoid weekend confusion.

Switching between brands: the concentration trap

When switching from one brand to another at the same labeled dose, expect a 2 to 4 week adjustment period. Serum estradiol levels will change even though the delivery rate is nominally the same.

The pattern we see most often in patients switching from brand-name to generic patches: breakthrough vasomotor symptoms starting in week 2 or 3 of the new patch, resolving after a dose increase. The reverse (switching from generic to brand-name) sometimes causes breast tenderness or bloating in week 1, which resolves as the body adjusts.

If you're switching brands:

1. Apply the first patch of the new brand on the same day you would have changed your old patch. Don't overlap.
2. Monitor symptoms daily for 4 weeks. Keep a log of hot flash frequency and severity.
3. If symptoms worsen, contact your provider at week 2. Don't wait until the scheduled follow-up.
4. If switching from a twice-weekly to a once-weekly patch (or vice versa), set a new calendar reminder immediately.

Insurance-driven switches: many insurers moved preferred coverage from Vivelle-Dot to generics in 2024 and 2025. If your pharmacy substitutes a generic without notification, check the patch size and brand name. If it's different from your previous fill, treat it as a new medication and monitor closely.

Storage, disposal, and adhesive failure troubleshooting

Storage: patches are stored at room temperature (68 to 77°F, 20 to 25°C). Don't refrigerate. Keep in the original foil pouch until use. Light and humidity degrade the adhesive.

Disposal: fold the used patch in half (sticky sides together) and dispose in household trash. The FDA recommends flushing only for fentanyl patches, not estradiol. Keep used patches away from children and pets. A used 0.1 mg/day patch still contains 6 to 7 mg of estradiol, which is a toxic dose for a small child.

Adhesive failure: if the patch edges lift or the patch falls off before the scheduled change day:

1. If fewer than 24 hours have passed since application: press the patch firmly for 10 seconds. If it re-adheres, continue wearing. If not, apply a new patch and reset your schedule to that day.
2. If more than 24 hours have passed: apply a new patch. Count this as the next scheduled change (don't try to "make up" the lost day).
3. If patches consistently fail to adhere for the full wear period: switch application sites. Avoid areas with lotion, powder, or recent shaving. The lower abdomen and buttocks have the best adhesion. Avoid the breasts (higher estradiol absorption, higher breast tenderness risk).

Some patients use medical adhesive (Skin Tac, Mastisol) around the patch edges. This works but can cause skin irritation. Tegaderm or other transparent dressings over the patch are off-label but effective for high-sweat situations (athletes, hot climates).

Skin irritation: rotate application sites. Don't apply a new patch to the same spot for at least 1 week. If redness or itching persists longer than 3 days after patch removal, switch brands. Different adhesives cause different rates of contact dermatitis. Vivelle-Dot has the lowest reported irritation rate (3.2% in clinical trials) because of its small size and acrylic adhesive (Archer et al., Menopause 2012).

When to call your provider about patch dosing

Contact your provider within 24 to 48 hours if:

• Hot flashes or night sweats return after months of good control on the same dose. This can indicate declining patch absorption (skin changes, scar tissue at application sites) or a need for dose escalation.
• You develop new-onset breast tenderness, swelling, or lumpiness that persists longer than 2 weeks. Estradiol stimulates breast tissue, and persistent tenderness can indicate the dose is too high or that you need progesterone opposition.
• You have unexpected vaginal bleeding. Any bleeding on estradiol-only therapy (without cyclic or continuous progesterone) requires endometrial evaluation.
• You develop signs of venous thromboembolism: unilateral leg swelling, calf pain, sudden shortness of breath, chest pain. Transdermal estradiol has lower VTE risk than oral (0.9 vs. 1.4 events per 1,000 woman-years), but risk is not zero (Vinogradova et al., BMJ 2019).
• You have signs of an allergic reaction to the adhesive: blistering, oozing, spreading rash beyond the patch border.

Most dose adjustments can wait until a scheduled follow-up. Breakthrough symptoms at the end of the wear period, mild skin irritation, and cosmetic concerns about patch size are not urgent.

FAQ

What is the starting dose for estradiol patches? For moderate to severe vasomotor symptoms, 0.05 mg/day is the standard starting dose. For mild symptoms or osteoporosis prevention, 0.025 mg/day. For severe or refractory symptoms, 0.075 to 0.1 mg/day.

How do I know which patch strength I'm using? The delivery rate is printed on the patch itself and on the foil pouch. Look for "0.05 mg/day" or similar. This is the daily absorption rate, not the total drug content.

Can I cut an estradiol patch in half to reduce the dose? No. Cutting disrupts the reservoir and causes uncontrolled release. If you need a lower dose, ask your provider for a different patch strength.

What's the difference between Climara and Vivelle-Dot? Climara is applied once weekly and has a larger surface area. Vivelle-Dot is applied twice weekly and is smaller. Both deliver the same daily estradiol dose at equivalent strengths, but serum levels differ slightly due to adhesive formulation.

Why is my generic estradiol patch a different size than my brand-name patch? Different manufacturers use different adhesive formulations and reservoir designs. A generic 0.05 mg/day patch delivers the same daily dose as the brand-name but may have a different surface area.

How long does it take for an estradiol patch to start working? Serum estradiol reaches steady state in 3 to 4 days. Symptom improvement (hot flash reduction) is usually noticeable within 1 to 2 weeks. Maximum effect occurs at 4 weeks.

Can I shower or swim with an estradiol patch? Yes. Patches are designed to stay on during bathing, swimming, and exercise. Pat dry after water exposure. Avoid hot tubs and saunas longer than 15 minutes, as heat increases absorption.

What if I forget to change my patch on schedule? If you're fewer than 24 hours late, change it as soon as you remember and continue your regular schedule. If more than 24 hours late, change it immediately and reset your schedule to the new day.

Why do I get hot flashes on the last day before changing my patch? The delivery rate decays slightly toward the end of the wear period. If this happens consistently, switch to a twice-weekly patch or increase the dose by one step.

Can I use two patches at once to double the dose? Only if prescribed. Some providers prescribe two 0.05 mg/day patches to achieve 0.1 mg/day if the single 0.1 mg/day patch isn't available. Don't do this without explicit instruction.

Do I need progesterone if I'm using an estradiol patch? If you have a uterus, yes. Unopposed estrogen increases endometrial cancer risk. You need either cyclic or continuous progesterone. If you've had a hysterectomy, progesterone is optional.

What's the maximum safe dose for estradiol patches? The FDA-approved maximum is 0.1 mg/day. Some providers prescribe higher doses off-label for refractory symptoms, but this increases breast cancer and cardiovascular risk.

Sources

1. Simon JA et al. Comparative pharmacokinetics and pharmacodynamics of transdermal estradiol delivery systems. Menopause. 2007.
2. Kuhl H et al. Pharmacokinetics of estradiol, free and total estrone, and sex hormone-binding globulin after single and multiple doses of a 17β-estradiol gel. Climacteric. 2005.
3. Pickar JH et al. Comparative steady-state pharmacokinetics of three transdermal estradiol replacement therapies in postmenopausal women. Menopause. 2019.
4. Santen RJ et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. Journal of Clinical Endocrinology & Metabolism. 2010.
5. Thurston RC et al. Adiposity and hot flashes in midlife women: a modifying role of age. Obstetrics & Gynecology. 2011.
6. North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022.
7. Stuenkel CA et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. Menopause. 2021.
8. Notelovitz M et al. Comparative pharmacokinetics of Climara and Vivelle transdermal estradiol systems. American Journal of Obstetrics & Gynecology. 2000.
9. Archer DF et al. A comparative study of transdermal matrix estradiol delivery systems. Menopause. 2012.
10. Vinogradova Y et al. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019.
11. Rossouw JE et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002.
12. Shifren JL et al. Transdermal versus oral estrogen therapy in postmenopausal women: a systematic review. Menopause. 2020.
13. Goodman MP et al. Comparison of compounded bioidentical hormone therapy and FDA-approved hormone therapy: a review. Menopause. 2021.
14. Pinkerton JV et al. Estrogen and selective estrogen receptor modulator effects on bone in postmenopausal women. Journal of Clinical Endocrinology & Metabolism. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Climara, Vivelle-Dot, Estraderm, Alora, Menostar, and Minivelle are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.